Tag: Biotech and Pharma

J&J’s stock surrenders early gains as weak sales guidance offsets earnings beat

Johnson & Johnson’s stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered some mixed guidance.

Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares fall

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.

China Disease Control Agency Detects Cluster of New Mpox Strain

China has detected the new mutated strain of the mpox virus for the first time, as the pathogen spreads to more geographies after the World Health Organization declared the outbreak in Africa a new global health emergency last year.

Lavipharm: Deal με Deca Investments για τη θυγατρική Pharma Plus

Το τίμημα της εξαγοράς περιλαμβάνει σταθερό ποσό ύψους 1,5 εκατ. ευρώ και μεταβλητό, το οποίο θα καθοριστεί με βάση τα μελλοντικά οικονομικά μεγέθη της εταιρείας.

Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations.

Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion.

Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion

Shares of Pfizer  were rising in premarket trading Tuesday after the drug company released financial guidance for 2025 that roughly lined up with Wall Street expectations.

Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly

Direct-to-consumer health-care startup Ro on Wednesday said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly, which aims to streamline access to the popular treatment.

Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial

Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk’s Wegovy, in the first head-to-head clinical trial on the weekly injections.

US FDA declines to approve Applied Therapeutics’ genetic disease drug

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic metabolic disease, casting a cloud over the company’s hopes for its first commercial product.

Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda.

Novo Nordisk Launches Wegovy in China With Prices Well Below US

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key to step in unlocking a big , fast- growing market for its blockbuster franchise 

Medicaid fuels US coverage of Novo, Lilly weight-loss drugs

U.S. government health plans account for the lion’s share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.

Bavarian Nordic Announces Interim Results for the First Nine Months of 2024

Bavarian Nordic A/S announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024.

Lavipharm: Εκρηκτική άνοδος 338,6% για τα καθαρά κέρδη στο εννεάμηνο – Στα 9,2 εκατ. ευρώ

Εκρηκτική άνοδο 338,6% στα 9,2 εκατ. ευρώ σημείωσαν τα συνολικά κέρδη μετά από φόρους της Lavipharm στο εννεάμηνο του 2024 (από 2,1 εκατ. ευρώ το 2023), λόγω της αναγνώρισης αναβαλλόμενης φορολογικής απαίτησης που προέρχεται από την απόφαση του Ομίλου να θέσει σε εκκαθάριση θυγατρικές εταιρείες οι οποίες στο παρελθόν είχαν σωρεύσει σημαντικές ζημίες.

Merck signs up to $3.3 bln cancer drug deal with China-based LaNova

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.

Merck’s stock slides as Q3 earnings beat estimates, but company lowers guidance

Merck & Co. Inc.’s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo.

Amgen stock falls as analysts mull over weight loss drug’s bone density data

Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide.

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi.

Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain.

Moderna’s third-quarter financial results look far better than analysts anticipated, but the beat seems largely to reflect Americans getting their Covid-19 shots earlier this year than they did last year.